Overview

Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)

Status:
Terminated
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to generate long-term safety, tolerability and efficacy data for AFQ056 in eligible adolescent patients with FXS who have participated in the CAFQ056B2214 study, the PK study CAFQ056B2131, or another study of AFQ056 which included FXS patients below 18 years of age provided the patient is at least 12 years of age at the time of entry into the current study.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals